DNA at a glance
Ginkgo Bioworks Holdings, Inc. (DNA, SEC CIK 1830214) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on August 6, 2026, an 8-K current report on August 5, 2026 and Form 4 insider filings as recently as September 16, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Ginkgo Bioworks Holdings, Inc. (DNA) reported revenue of $170.2 million (down 25.1% from FY2024) and a net loss of $312.8 million. Diluted EPS was -$5.64.
- The most recent insider open-market sale reported on Form 4 was by HENRY CHRISTIAN O on September 15, 2026 of 5,000 shares at $7.08 per share.
- In the last 90 days, DNA insiders reported 0 open-market purchases ($0) and 3 open-market sales ($44K) on Form 4, a net sale of $44K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $170.2M
- −25.1% vs prior year
- Insiders · 90 days
- 0 buys · 3 sells
- Net −$44K
- Latest 8-K
- Aug 5, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Revenue $20.2M, down $19.0M YoY from $39.1M, driven by reduced large-enterprise programs
- Operating margin -290.5% vs -148.7% YoY, based on operating losses of $58.5M and $58.2M
- R&D expenses $46.2M, down $7.2M YoY; G&A expenses $30.8M, down $4.2M
- Interest income $3.2M vs $6.1M, reflecting lower average cash balances
- 2026 R&D and G&A expenses expected consistent or declining; tools investment could increase R&D
Risk Factors
- No risk-factors section provided; supplied text contains Items 2–6 and signatures only
- Newly disclosed transaction: Tower Biosecurity stock purchase agreement dated February 26, 2026
- Regulatory, legal, liquidity, competitive, and market risks not assessable from provided text
AI summary of the DNA 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 results released for quarter ended June 30, 2026
- Full financial figures and management commentary contained in Exhibit 99.1
Item EX-99.1: Item EX-99.1
- Q2 revenue $20.2M, down 48% from $39.1M, reflecting restructuring-driven program rationalization
- Continuing-operations net loss widened to $57.3M from $53.2M; Adjusted EBITDA loss reached $36.3M versus $25.4M
Item 7.01: Regulation FD Disclosure
- Q2 2026 business-performance presentation scheduled for August 5, 2026, at 4:30 p.m. ET
- Investor Q&A and webcast access through Ginkgo’s investor-relations website
Item 5.07: Submission of Matters to a Vote of Security Holders
- Six director nominees elected, preserving board continuity through the next annual meeting
- Dual-class voting concentrated influence: Class B holders cast 10 votes per share and separately elected Jason Kelly and Reshma Shetty
AI summaries of DNA 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for DNA
Don't miss the next DNA filing
- Alerts as it files. A push when DNA files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut DNA, by share count.
- Ask anything. An AI agent that reads every DNA filing and answers with sources.
DNA alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| HENRY CHRISTIAN O | Sell | Sep 15, 2026 | 5,000 | $7.08 |
| Coen Steven P. | Sell | Aug 24, 2026 | 330 | $6.98 |
| Coen Steven P. | M | Aug 21, 2026 | 587 | - |
| Coen Steven P. | M | Aug 21, 2026 | 156 | - |
| Coen Steven P. | M | Aug 21, 2026 | 587 | - |
| Coen Steven P. | M | Aug 21, 2026 | 156 | - |
| Canton Barry | A | Jul 28, 2026 | 117,135 | - |
| Shetty Reshma P. | A | Jul 28, 2026 | 127,423 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | $251.5M | $227.0M | $170.2M |
| Operating Income | - | -$559.8M | -$315.3M |
| Net Income | -$892.9M | -$547.0M | -$312.8M |
| Op. Margin | - | -246.5% | -185.3% |
| Net Margin | -355.1% | -240.9% | -183.8% |
| Balance Sheet | |||
| Total Assets | - | $1.4B | $1.1B |
| Equity | - | $716.1M | $508.6M |
| ROE | - | -76.4% | -61.5% |
| Per Share | |||
| EPS | $-0.46 | $-10.54 | $-5.64 |
| Cash Flow | |||
| Operating CF | - | -$319.6M | -$171.1M |
| CapEx | $40.8M | $62.5M | $7.7M |
Source: XBRL data in Ginkgo Bioworks Holdings, Inc. (DNA)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
DNA filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Sep 16, 2026 | - | - | - |
| 4 | Aug 25, 2026 | - | - | - |
| 10-Q | Aug 6, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 5, 2026 | - | Analysis | - |
| 4 | Jul 30, 2026 | - | - | - |
| 8-K | Jul 30, 2026 | - | Analysis | - |
| 4 | Jul 30, 2026 | - | - | - |
| 4 | Jul 30, 2026 | - | - | - |
| 4 | Jul 20, 2026 | - | - | - |
| 4 | Jun 15, 2026 | - | - | - |
| 4 | Jun 15, 2026 | - | - | - |
| 4 | Jun 15, 2026 | - | - | - |
| 4 | Jun 15, 2026 | - | - | - |
| 8-K | Jun 12, 2026 | - | Analysis | - |
| 4 | May 26, 2026 | - | - | |
| 10-Q | May 7, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | May 7, 2026 | - | Analysis | |
| 4 | Apr 20, 2026 | - | - | - |
| 4 | Apr 14, 2026 | - | - | - |
| 4 | Apr 13, 2026 | - | - | - |
| 4 | Apr 13, 2026 | - | - | - |
| 4 | Apr 10, 2026 | - | - | - |
| 4 | Apr 10, 2026 | - | - | - |
| 4 | Apr 10, 2026 | - | - | - |
| 8-K | Apr 7, 2026 | - | Analysis | - |
Related Health Care companies
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- ADPT · Adaptive Biotechnologies CorpBiological Products, (No Diagnostic Substances)
- ADMA · ADMA BIOLOGICS, INC.Biological Products, (No Diagnostic Substances)
- ALEC · Alector, Inc.Biological Products, (No Diagnostic Substances)
- ALLO · Allogene Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AMGN · AmgenBiological Products, (No Diagnostic Substances)
- AVXL · ANAVEX LIFE SCIENCES CORP.Biological Products, (No Diagnostic Substances)
- APGE · Apogee Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
DNA SEC filings: frequently asked questions
Are DNA insiders buying or selling?
In the last 90 days, Ginkgo Bioworks Holdings, Inc. (DNA) officers, directors and 10% owners reported no open-market purchases and 3 open-market sales worth $43,650 by 2 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
What was DNA's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Ginkgo Bioworks Holdings, Inc. (DNA) reported revenue of $170.2 million (down 25.1% from FY2024) and a net loss of $312.8 million. Diluted EPS was -$5.64. The figures come from the XBRL data in the 10-K.
What did DNA report in its latest 8-K?
Ginkgo Bioworks Holdings, Inc. (DNA) filed an 8-K on August 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q2 2026 results released for quarter ended June 30, 2026.
What are the latest DNA SEC filings?
Ginkgo Bioworks Holdings, Inc. (DNA) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on August 6, 2026, an 8-K current report on August 5, 2026 and a Form 4 insider filing on September 16, 2026.
What is DNA's SEC CIK number?
Ginkgo Bioworks Holdings, Inc. (DNA)'s SEC Central Index Key (CIK) is 1830214. EDGAR lists every DNA filing under that number.
Ask anything about DNA
The research agent reads DNA's filings, financials, insider trades and 13F holders, then answers with sources.